Sampaio Roney O, Grinberg Max, Leite João J, Tarasoutchi Flávio, Chalela William A, Izaki Marisa, Spina Guilherme S, Rossi Eduardo Giusti, Mady Charles
Department of Valvular Heart Disease, University of São Paulo Medical School, São Paulo, Brazil.
Am J Cardiol. 2005 Jul 1;96(1):117-21. doi: 10.1016/j.amjcard.2005.02.056.
The effects of 12 months of therapy were evaluated in 47 mildly symptomatic patients with moderate to severe mitral valve regurgitation; 26 patients received enalapril and 21 received a placebo. Enalapril was associated with a significant reduction in left ventricular diameter and mitral regurgitation volume, with no evidence of change in systolic function indexes. However, enalapril did not hinder progressive aerobic impairment to effort.
对47例轻症状的中重度二尖瓣反流患者进行了为期12个月的治疗效果评估；26例患者接受依那普利治疗，21例患者接受安慰剂治疗。依那普利可使左心室直径和二尖瓣反流容积显著降低，且收缩功能指标无变化迹象。然而，依那普利并未阻碍运动时进行性有氧功能损害。
